Patient characteristics, operative factors, postoperative morbidity, and mortality
The clinical characteristics of the 739 patients are shown in Table 1. Altogether, 460 patients had comorbidities, including 135 patients with malignant disease (25 with colon cancer, 10 with rectal cancer, 27 with gastric cancer, 3 with esophageal cancer, 16 with breast cancer, 12 with prostate cancer, 10 with bladder cancer, 3 with gallbladder cancer, 10 with thyroid cancer, 5 with renal cancer, 6 with laryngeal cancer, 5 with pharyngeal cancer, 2 with tongue cancer, and 8 with lymphoma; duplication occurred in some patients), 127 patients with hypertension, 115 with diabetes mellitus, 50 with angina pectoris, 45 with COPD, 34 with cerebral infarction, 27 with arrhythmia (25 with atrial fibrillation, 1 with paroxysmal supraventricular tachycardia, and 1 with atrioventricular block), 23 with interstitial lung disease, 23 with asthma, 21 with autoimmune disease, and 9 with chronic renal failure.
Table 1
Patient characteristics and perioperative data
Variables | |
Sex (man / woman) | 457 / 282 |
Age, medial, range (y) | 70 (33 – 92) |
Comorbidity | 460 (62.2%) |
Malignant disease | 135 (18.2%) |
Hypertension | 127 (17.2%) |
Diabetes mellitus | 115 (15.5%) |
Angina pectoris | 50 (6.8%) |
COPD | 45 (6.1%) |
Cerebral infarction | 34 (4.6%) |
Arrhythmia | 27 (3.6%) |
Interstitial lung disease | 23 (3.1%) |
Asthma | 23 (3.1%) |
Autoimmune disease | 21 (2.8%) |
Chronic renal failure | 9 (1.2%) |
Body mass index, median (range) | 22.6 (14.3 – 36.6) |
CEA, median, range (ng/ml) | 3.4 (0.5 – 306) |
Brinkman index, median (range) | 600 (0 – 3600) |
PNI, median (range) | 49.8 (26.9 – 67.5) |
NLR, median (range) | 2.16 (0.53 – 12.65) |
%VC, median (range) | 110 (45.7 – 184.2) |
FEV1%, median (range) | 73.2 (30.5 – 108.8) |
Lobe of lung cancer (RU / RM / RL / LU / LL) | 220 / 41 / 181 / 175 / 122 |
pStage (0 / IA / IB / IIA / IIB / IIIA / IIIB / IV / yIA / yIIA) | 46 / 388 / 131 / 47 / 65 / 51 / 3 / 2 / 5 / 1 |
Histological type (Ad / Sq / LCNEC / AdSq / Pleo / Large / Carci) | 556 / 139 / 19 / 11 / 8 / 3 / 3 |
Operative approach (Open / VATS / RATS) | 71 / 662 / 6 |
Location of Lobectomy (RU / RM / RL / LU / LL) | 175 / 36 / 106 / 108 / 76 |
Operative procedure (Wedge / Seg / Lob / Lob+CW / Lob+Seg / Sleeve Lob / Bilob / Pneumo) | 154 / 68 / 473 / 9 / 3 / 4 / 10 / 18 |
Morbidity | 193 (26.1%) |
Air leakage | 93 (12.6%) |
Arrhythmia | 45 (6.1%) |
Atelectasis | 19 (2.5%) |
Pneumonia | 15 (2.0%) |
Attack of asthma | 4 (0.5%) |
Cerebral infarction | 3 (0.4%) |
Chylothorax | 2 (0.3%) |
Broncho-pleural fistula | 2 (0.3%) |
Clavien-Dindo grade (0 / 1 / 2 / 3a / 3b) | 546 / 1 / 76 / 111 / 5 |
Mortality | 1 (0.1%) |
Mortality or severe morbidity | 72 (9.7%) |
Tracheal or bronchial fistula | 2 (0.3%) |
Respiratory disfunction | 4 (0.5%) |
NCD risk score | |
Mortality, median (range) (%) | 0.2 (0 – 10.6) |
Mortality or severe morbidity, median (range) (%) | 3.7 (0.5 – 39.3%) |
Tracheal or bronchial fistula, median (range) (%) | 0.1 (0 – 8.1) |
Respiratory disfunction, median (range) (%) | 0.2 (0 – 8.2) |
COPD; chronic obstructive pulmonary disease, CEA; carcinoembryonic antigen, PNI; prognostic nutritional index, NLR; neutrophil-to-lymphocyte ratio, VC; vital capacity, FEV1%; forced expiratory volume % in one second, RU; right upper, RM; right middle, RL; right lower, LU; left upper, LL; left lower, p; pathological, y; yield to treatment, Ad; adenocarcinoma, Sq; squamous cell carcinoma, LCNEC; large cell neuroendocrine carcinoma, AdSq; adenosquamous cell carcinoma, Large; large cell carcinoma, Carci; carcinoid, Open; open thoracotomy, VATS; video-assisted thoracic surgery, RATS; robotic-assisted thoracic surgery, RU; right upper, RM; right middle, RL; right lower, LU; left upper, LL; left lower, RU; right upper, RM; right middle, RL; right lower, LU; left upper, LL; left lower, Wedge; wedge resection, Seg; segmentectomy, Lob; lobectomy, CW; chest wall resection, Bilob; bi-lobectomy, Pneumo; pneumonectomy, NCD; national clinical database. |
Postoperative morbidities were observed in 193 patients (26.1%). Clavien-Dindo grade I complication was noted in 1 patient, grade II in 76, grade IIIa in 111, and grade IIIb in 5. Air leakage occurred in 93 patients, arrhythmia in 45 (atrial fibrillation in 38, paroxysmal supraventricular tachycardia in 3, ventricular tachycardia in 3, and sick sinus syndrome in 1), atelectasis in 19, pneumonia in 15, asthma attacks in 4, cerebral infarction in 3, chylothorax in 2, and bronchopleural fistula in 2. Minor but serious postoperative complications included postoperative bleeding in one patient and right middle lobe torsion in another patient. All complications were resolved surgically.
Postoperative death was noted in 1 patient, and the mortality rate was 0.1%. Mortality and severe morbidities according to the RC-NCD were observed in 72 patients (9.7%); the severe morbidities were respiratory failure in 4 patients, tracheobronchial fistula in 2, pneumonia in 15, redo surgery in 2 (including postoperative bleeding in 1), arrhythmia requiring therapy in 45 (atrial fibrillation in 38, paroxysmal supraventricular tachycardia in 3, ventricular tachycardia in 3, and sick sinus syndrome in 1), and chylothorax in 2.
The median mortality rate according to the RC-NCD was 0.2%, the median mortality and severe morbidity rate was 3.7%, the median incidence rate of tracheal or bronchial fistula was 0.1%, and the median incidence rate of respiratory dysfunction was 0.2%.
Results of the univariate analysis
The relationships between patient characteristics or operative factors and postoperative morbidity or severe morbidity were analyzed (Table 2). Postoperative morbidities were more likely to be associated with the coexistence of asthma (p<0.01), smoking status (p<0.01), CEA (p=0.04), NLR>1.56 (p=0.03), FEV1%<70 (p<0.01), pulmonary lobe (right upper or right lower or left upper) (p<0.01), and lobectomy (p<0.01) than other factors. Severe postoperative morbidity was more likely to be associated with smoking status (p=0.03), high BMI (p<0.01), coexistence of asthma (p<0.01), low %VC (p=0.02), squamous cell carcinoma (p<0.01), open thoracotomy (p=0.03), and lobectomy (p<0.01) than other factors. Significant risk factors for other postoperative complications could not be assessed because of the small number of patients with these complications.
Table 2
Univariate analysis of postoperative morbidity and severe morbidity
Variables | | Morbidity | P value | Severe morbidity | P value |
| | Absent, n (%) | Present, n (%) | | Absent, n (%) | Present, n (%) | |
Sex | Man | 339 (74.2) | 118 (25.8) | 0.81 | 406 (88.8) | 51 (11.2) | 0.09 |
| Woman | 207 (73.4) | 75 (26.6) | | 261 (92.5) | 21 (7.5) | |
Age | ≥ 75 | 160 (78.1) | 45 (21.9) | 0.11 | 191 (93.2) | 14 (6.8) | 0.09 |
| < 75 | 386 (72.3) | 148 (27.7) | | 476 (89.1) | 58 (10.9) | |
Comorbidity | | | | | | | |
Malignant disease | Absent | 438 (72.5) | 166 (27.5) | 0.07 | 540 (89.4) | 64 (10.6) | 0.09 |
| Present | 108 (80.0) | 27 (20.0) | | 127 (94.1) | 8 (5.9) | |
Angina pectoris | Absent | 512 (74.3) | 177 (25.7) | 0.32 | 512 (74.3) | 177 (25.7) | 0.32 |
| Present | 34 (68.0) | 16 (32.0) | | 34 (68.0) | 16 (32.0) | |
Cerebral infarction | Absent | 520 (73.8) | 185 (26.2) | 0.72 | 634 (89.9) | 71 (10.1) | 0.17 |
| Present | 64 (76.5) | 8 (23.5) | | 33 (97.1) | 1 (2.9) | |
Interstitial lung disease | Absent | 526 (73.5) | 190 (26.5) | 0.14 | 648 (90.5) | 68 (9.5) | 0.20 |
| Present | 20 (87.0) | 3 (13.0) | | 19 (82.6) | 4 (17.4) | |
Chronic renal failure | Absent | 541 (74.1) | 189 (25.9) | 0.20 | 659 (90.3) | 71 (9.7) | 0.88 |
| Present | 7 (55.6) | 4 (44.4) | | 8 (88.9) | 1 (11.1) | |
Diabetes mellitus | Absent | 461 (73.9) | 163 (26.1) | 0.99 | 562 (90.1) | 62 (9.9) | 0.68 |
| Present | 85 (73.9) | 30 (26.1) | | 105 (91.3) | 10 (8.7) | |
COPD | Absent | 517 (74.5) | 177 (25.5) | 0.13 | 629 (90.6) | 65 (9.4) | 0.17 |
| Present | 29 (64.4) | 16 (35.6) | | 38 (84.4) | 7 (15.6) | |
Asthma | Absent | 535 (74.7) | 181 (25.3) | < 0.01 | 647 (90.4) | 69 (9.6) | 0.58 |
| Present | 11 (47.8) | 12 (52.2) | | 20 (87.0) | 3 (13.0) | |
Arrhythmia | Absent | 525 (73.7) | 187 (26.3) | 0.63 | 642 (90.2) | 70 (9.8) | 0.67 |
| Present | 21 (77.8) | 6 (22.2) | | 25 (95.6) | 2 (7.4) | |
Autoimmune disease | Absent | 528 (73.5) | 190 (26.5) | 0.21 | 648 (90.3) | 70 (9.8) | 0.97 |
| Present | 18 (85.7) | 3 (14.3) | | 19 (90.5) | 2 (9.5) | |
Hypertension | Absent | 450 (73.5) | 162 (26.5) | 0.63 | 450 (73.5) | 162 (26.5) | 0.63 |
| Present | 96 (75.6) | 31 (24.4) | | 96 (75.6) | 31 (24.4) | |
Smoking status | Brinkman index < 600 | 289 (79.6) | 74 (20.4) | < 0.01 | 336 (92.6) | 27 (7.4) | 0.03 |
| Brinkman index ≥ 600 | 257 (68.4) | 119 (31.6) | | 331 (88.0) | 45 (12.0) | |
BMI | < 22.93 | 295 (75.5) | 96 (24.5) | 0.30 | 366 (93.6) | 25 (6.4) | < 0.01 |
| ≥ 22.93 | 251 (72.1) | 97 (27.9) | | 301 (86.5) | 47 (13.5) | |
CEA | ≤ 5 | 392 (76.0) | 124 (24.0) | 0.04 | 469 (90.9) | 47 (9.1) | 0.37 |
| > 5 | 154 (69.1) | 69 (30.9) | | 198 (88.8) | 25 (11.2) | |
PNI | ≥ 49.68 | 290 (76.3) | 90 (23.7) | 0.12 | 350 (92.1) | 30 (7.9) | 0.08 |
| < 49.68 | 256 (71.3) | 103 (28.7) | | 317 (88.3) | 42 (11.7) | |
NLR | ≤ 1.56 | 140 (80.0) | 35 (20.0) | 0.03 | 160 (91.4) | 15 (8.6) | 0.54 |
| > 1.56 | 406 (72.0) | 158 (28.0) | | 507 (89.9) | 57 (10.1) | |
%VC | ≥ 80 | 532 (74.1) | 186 (25.9) | 0.44 | 651 (90.7) | 67 (9.3) | 0.02 |
| < 80 | 14 (66.7) | 7 (33.3) | | 16 (76.2) | 5 (23.8) | |
FEV1% | ≥ 70 | 363 (78.2) | 101 (21.8) | < 0.01 | 424 (91.4) | 40 (8.6) | 0.18 |
| < 70 | 183 (66.6) | 92 (33.4) | | 243 (88.4) | 32 (11.6) | |
Pulmonary lobe of NSCLC | RUL | 156 (70.9) | 64 (29.1) | < 0.01 | 196 (89.1) | 24 (10.9) | 0.32 |
| RML | 36 (85.7) | 6 (14.3) | | 39 (92.9) | 3 (7.1) | |
| RLL | 136 (75.6) | 44 (24.4) | | 164 (91.1) | 16 (8.9) | |
| LUL | 117 (66.9) | 58 (33.1) | | 153 (87.4) | 22 (12.6) | |
| LLL | 101 (82.8) | 21 (17.2) | | 115 (94.3) | 7 (5.7) | |
| RUL or RLL or LUL | 409 (71.1) | 166 (28.9) | < 0.01 | 513 (89.2) | 62 (10.8) | 0.07 |
| RML or LLL | 137 (83.5) | 27 (16.5) | | 154 (93.9) | 10 (6.1) | |
Histological type | Non-Squamous cell carcnimoma | 452 (75.3) | 148 (24.7) | 0.06 | 551 (91.8) | 49 (8.2) | <0.01 |
| Squamous cell carcinoma | 94 (67.6) | 45 (32.4) | | 116 (83.5) | 23 (16.6) | |
Operative approach | VATS or RATS | 495 (74.1) | 173 (25.9) | 0.67 | 608 (91.0) | 60 (9.0) | 0.03 |
| Open thoracotomy | 51 (71.8) | 20 (28.2) | | 59 (83.1) | 12 (16.9) | |
Operative procedure | Except for wedge resection | 409 (69.9) | 176 (30.1) | < 0.01 | 518 (88.6) | 67 (11.4) | < 0.01 |
| Wedge resection | 137 (89.0) | 17 (11.0) | | 149 (96.8) | 5 (3.2) | |
| Except for segmentectomy | 493 (73.5) | 178 (26.5) | 0.42 | 493 (73.5) | 178 (26.5) | 0.42 |
| Segmentectomy | 53 (77.9) | 15 (22.1) | | 53 (77.9) | 15 (22.1) | |
| Except for lobectomy | 215 (80.8) | 51 (19.2) | < 0.01 | 215 (80.8) | 51 (19.2) | < 0.01 |
| Lobectomy | 331 (70.0) | 142 (30.0) | | 331 (70.0) | 142 (30.0) | |
| Except for extend-lobectomy | 533 (74.8) | 180 (25.3) | < 0.01 | 533 (74.8) | 180 (25.3) | < 0.01 |
| Extend-lobectomy | 13 (50.0) | 13 (50.0) | | 13 (50.0) | 13 (50.0) | |
| Except for pneumonectomy | 534 (74.1) | 187 (25.9) | 0.48 | 534 (74.1) | 187 (25.9) | 0.48 |
| Pneumonectomy | 12 (66.7) | 6 (33.3) | | 12 (66.7) | 6 (33.3) | |
COPD; chronic obstructive pulmonary disease, BMI; body mass index, CEA; carcinoembryonic antigen, PNI; prognostic nutritional index, NLR; neutrophil-to-lymphocyte ratio, VC; vital capacity, FEV1%; forced expiratory volume % in one second, NSCLC; non-small cell lung cancer, RUL; right upper lobe, RML; right middle lobe, RLL, right lower lobe, LUL; left upper lobe, LLL; left lower lobe, PNI; prognostic nutritional index, NLR; neutrophil-to-lymphocyte ratio, VATS; video-assisted thoracic surgery, RATS; robotic-assisted thoracic surgery. |
Results of the multivariate analysis
Multivariate analyses of the risk factors for postoperative morbidities are presented in Table 3. The coexistence of asthma (odds ratio [OR] 2.78, 95% confidence interval [CI] 1.136–6.822, p=0.02), smoking status (OR 1.46, 95% CI 1.004–2.139, p=0.04), low FEV1% (OR 1.55, 95% CI 1.068–2.265, p=0.02), and pulmonary lobe (right upper or right lower or left upper) (p<0.01) were identified as significant risk factors for postoperative morbidity, while wedge resection (OR 0.26, 95% CI 0.152–0.453 p<0.01) had an extremely low risk of postoperative morbidity. Furthermore, the BMI (OR 2.06, 95% CI 1.228-3.471, p<0.01) was identified as a significant risk factor for severe postoperative morbidity, while wedge resection (OR 0.26, 95% CI 0.103–0.681, p<0.01) was again associated with an extremely low risk of severe postoperative morbidity.
Table 3
Multivariate analysis of risk factors for postoperative morbidity and severe postoperative morbidity
Postoperative morbidity |
Variables | | Odds ratio | 95% CI | P value |
Comorbidity | Asthma | 2.78 | 1.136-6.822 | 0.02 |
Smoking status | Brinkman index ≥ 600 | 1.46 | 1.004-2.139 | 0.04 |
CEA | > 5 | 1.31 | 0.905-1.906 | 0.15 |
FEV1% | < 70 | 1.55 | 1.068-2.265 | 0.02 |
NLR | > 1.56 | 1.44 | 0.935-2.216 | 0.09 |
Pulmonary lobe | RUL or RLL or LUL | 2.01 | 1.265-3.224 | < 0.01 |
Operative procedure | Wedge resection | 0.26 | 0.152-0.453 | < 0.01 |
Postoperative severe morbidity |
Smoking status | Brinkman index ≥ 600 | 1.38 | 0.789-2.421 | 0.25 |
BMI | ≥ 22.93 | 2.06 | 1.228-3.471 | < 0.01 |
%VC | < 80 | 2.94 | 0.961-8.999 | 0.05 |
Histological type | Squamous cell carcinoma | 1.63 | 0.880-3.028 | 0.11 |
Operative approach | Open thoracotomy | 1.67 | 0.826-3.376 | 0.15 |
Operative procedure | Wedge resection | 0.26 | 0.103-0.681 | < 0.01 |
CEA; carcinoembryonic antigen, FEV1%; forced expiratory volume % in one second, NLR; neutrophil-to-lymphocyte ratio, BMI; body mass index, VC; vital capacity |
Results of the sub-analysis
We analyzed the risk factors for postoperative morbidity in patients who underwent lobectomy as a sub-analysis. The clinical characteristics of the 473 patients who underwent lobectomy are shown in Table 4. Among these, 163 underwent right upper lobectomy (RUL), 37 underwent right middle lobectomy (RML), 94 underwent right lower lobectomy (RLL), 105 underwent left upper lobectomy (LUL), and 74 underwent left lower lobectomy (LLL). Postoperative morbidities were observed in 142 patients (30.0%). A Clavien-Dindo grade I complication was noted in 1 patient, grade II in 54, grade IIIa in 83, and grade IIIb in 4. The mortality rate was 0. Mortality and severe morbidities according to the RC-NCD were observed in 52 patients (10.9%). The median mortality rate according to the RC-NCD was 0.2%, the median mortality and severe morbidity rate was 4.6%, the median incidence rate of tracheal or bronchial fistula was 0.2%, and the median incidence rate of respiratory dysfunction was 0.2%.
Table 4
Patient characteristics and perioperative data received lobectomy
Variables | |
Sex (man / woman) | 303 / 170 |
Age, medial, range (y) | 69 (34 – 92) |
Comorbidity | 232 (53.1%) |
Malignant disease | 58 (12.2%) |
Hypertension | 73 (15.4%) |
Diabetes mellitus | 71 (15.0%) |
Angina pectoris | 32 (6.8%) |
COPD | 29 (6.1%) |
Cerebral infarction | 20 (4.2%) |
Arrhythmia | 16 (3.4%) |
Interstitial lung disease | 7 (1.5%) |
Asthma | 14 (2.9%) |
Autoimmune disease | 11 (2.3%) |
Chronic renal failure | 6 (1.2%) |
Body mass index, median (range) | 22.9 (14.3 – 36.6) |
CEA, median, range (ng/ml) | 3.4 (0.5 – 269) |
Brinkman index, median (range) | 600 (0 – 3600) |
PNI, median (range) | 50.1 (31.8 – 64.2) |
NLR, median (range) | 2.07 (0.77 – 12.65) |
%VC, median (range) | 111.2 (45.7 – 184.2) |
FEV1%, median (range) | 73.8(30.5 – 99.5) |
pStage (0 / IA / IB / IIA / IIB / IIIA / IIIB / IV / yIA) | 16 / 234 / 97 / 39 / 43 / 36 / 3 / 2 / 3 |
Histological type (Ad / Sq / LCNEC / AdSq / Pleo / Large / Carci) | 362 / 81 / 14 / 8 / 2 / 3 / 3 |
Operative approach (Open / VATS / RATS) | 48 / 419 / 6 |
Operative procedure | |
RUL | 163 (34.5%) |
RML | 37 (7.8%) |
RLL | 94 (19.8%) |
LUL | 105 (22.2%) |
LLL | 74 (15.6%) |
Morbidity | 142 (30.0%) |
Air leakage | 67 (14.1%) |
Arrhythmia | 35 (7.4%) |
Atelectasis | 16 (3.4%) |
Pneumonia | 8 (1.7%) |
Attack of asthma | 3 (0.6%) |
Cerebral infarction | 3 (0.6%) |
Chylothorax | 2 (0.4%) |
Broncho-pleural fistula | 1 (0.2%) |
Clavien-Dindo grade (0 / 1 / 2 / 3a / 3b) | 331 / 1 / 54 / 83 / 4 |
Mortality | 0 (0%) |
Mortality or severe morbidity | 52 (10.9%) |
Tracheal or bronchial fistula | 1 (0.2%) |
Respiratory disfunction | 4 (0.8%) |
NCD risk score | |
Mortality, median (range) (%) | 0.2 (0 – 10.3) |
Mortality or severe morbidity, median (range) (%) | 4.6 (1.2 – 27.3) |
Tracheal or bronchial fistula, median (range) (%) | 0.2 (0 – 3.4) |
Respiratory disfunction, median (range) (%) | 0.2 (0 – 4.4) |
COPD; chronic obstructive pulmonary disease, CEA; carcinoembryonic antigen, PNI; prognostic nutritional index, NLR; neutrophil-to-lymphocyte ratio, VC; vital capacity, FEV1%; forced expiratory volume % in one second, p; pathological, y; yield to treatment, Ad; adenocarcinoma, Sq; squamous cell carcinoma, LCNEC; large cell neuroendocrine carcinoma, AdSq; adenosquamous cell carcinoma, Large; large cell carcinoma, Carci; carcinoid, Open; open thoracotomy, VATS; video-assisted thoracic surgery, RATS; robotic-assisted thoracic surgery RUL; right upper lobectomy, RML; right middle lobectomy, RLL; right lower lobectomy, LUL; left upper lobectomy, LLL; left lower lobectomy, NCD; national clinical database. |
The comparison between the risk score according to the RC-NCD and postoperative morbidity by lobes is shown in Table 5. Although the risk scores for mortality or severe morbidity according to the RC-NCD were extremely high in RUL and RLL, the mortality and severe morbidity rates were not significantly different among lobes, although the morbidity rate tended to be high in RUL, RLL, and LUL.
Table 5
Comparison between risk score according to RC-NCD and postoperative morbidity by lobes.
Procedure | RUL | RML | RLL | LUL | LLL | P value |
NCD risk score | | | | | | |
Mortality, median (range) (%) | 0.3 (0-2.5) | 0.1 (0-1.1) | 0.4 (0-10.3) | 0.1 (0-2.4) | 0.1 (0-4.3) | < 0.01 |
Mortality or severe morbidity, median (range) (%) | 5.7 (1.8-19.7) | 2.6 (1.2-12.2) | 5.3 (1.8-27.3)) | 3.7 (1.2-21.6) | 2.9 (1.2-16.5) | < 0.01 |
Tracheal or bronchial fistula, median (range) (%) | 0.2 (0-0.6) | 0.1 (0-0.8) | 0.6 (0.1-3.4) | 0.2 (0-0.6) | 0.1 (0-1.1) | < 0.01 |
Respiratory disfunction, median (range) (%) | 0.2 (0-1.4) | 0.1 (0-0.7) | 0.2 (0-2.5) | 0.2 (0-2.5) | 0.1 (0-4.4) | < 0.01 |
Clinical data | | | | | | |
Mortality or severe morbidity (%) | 11.6 | 8.1 | 9.6 | 17.1 | 4.1 | 0.08 |
Tracheal or bronchial fistula (%) | 0 | 0 | 0 | 0.9 | 0 | 0.47 |
Respiratory disfunction (%) | 0.6 | 0 | 1.1 | 1.9 | 0 | 0.64 |
Morbidity (%) | 32.5 | 16.2 | 32.9 | 35.2 | 20.3 | 0.06 |
Air leakage (%) | 14.7 | 5.4 | 18.1 | 14.3 | 12.1 | 0.43 |
Arrhythmia (%) | 7.9 | 8.1 | 5.3 | 11.4 | 2.7 | 0.23 |
Pneumonia (%) | 1.2 | 0 | 2.1 | 2.8 | 1.3 | 0.76 |
Atelectasis (%) | 4.9 | 2.7 | 3.2 | 1.9 | 2.7 | 0.73 |
RC-NCD; risk calculator of national clinical database, RUL; right upper lobectomy, RML; right middle lobectomy, RLL; right lower lobectomy, LUL; left upper lobectomy, LLL; left lower lobectomy. |
The relationships between patient characteristics or operative factors and postoperative morbidity or severe morbidity for patients who underwent lobectomy were analyzed (Table 6). Postoperative morbidities tended to be associated with the coexistence of chronic renal failure (p=0.04), coexistence of asthma (p<0.04), smoking status (p<0.01), CEA (p=0.04), NLR>1.56 (p=0.01), FEV1%<70 (p<0.01), and RUL, RLL, or LUL (p<0.01). Severe postoperative morbidity tended to be associated with male sex (p=0.01), a high BMI (p<0.01), low %VC (p<0.02), squamous cell carcinoma (p=0.04), and RUL, RLL, or LUL (p=0.03).
Table 6
Univariate analysis of risk factors for postoperative morbidity and severe morbidity in patients received lobectomy
Variables | | Morbidity | P value | Severe morbidity | P value |
| | Absent, n (%) | Present, n (%) | | Absent, n (%) | Present, n (%) | |
Sex | Man | 209 (68.9) | 94 (31.1) | 0.52 | 262 (86.5) | 41 (13.5) | 0.01 |
| Woman | 122 (71.8) | 48 (28.2) | | 159 (93.5) | 11 (6.5) | |
Age | ≥ 75 | 77 (72.6) | 29 (27.4) | 0.49 | 94 (88.7) | 12 (11.3) | 0.90 |
| < 75 | 254 (69.2) | 113 (30.8) | | 327 (89.1) | 40 (10.9) | |
Comorbidity | | | | | | | |
Malignant disease | Absent | 288 (69.4) | 127 (30.6) | 0.46 | 369 (88.9) | 46 (11.1) | 0.86 |
| Present | 43 (74.1) | 15 (25.9) | | 52 (89.7) | 6 (10.3) | |
Angina pectoris | Absent | 311 (70.5) | 130 (29.5) | 0.33 | 392 (88.9) | 49 (11.1) | 0.76 |
| Present | 20 (62.5) | 12 (37.5) | | 29 (90.6) | 3 (9.4) | |
Cerebral infarction | Absent | 318 (70.2) | 135 (29.8) | 0.61 | 402 (88.7) | 51 (11.3) | 0.38 |
| Present | 13 (65.0) | 7 (35.0) | | 19 (95.0) | 1 (5.0) | |
Interstitial lung disease | Absent | 325 (69.7) | 141 (30.3) | 0.36 | 415 (89.1) | 51 (10.9) | 0.77 |
| Present | 6 (85.7) | 1 (14.3) | | 6 (85.7) | 1 (14.3) | |
Chronic renal failure | Absent | 329 (70.5) | 138 (29.5) | 0.04 | 416 (89.1) | 51 (10.9) | 0.65 |
| Present | 2 (33.3) | 4 (66.7) | | 5 (83.3) | 1 (16.7) | |
Diabetes mellitus | Absent | 284 (70.7) | 118 (29.3) | 0.45 | 358 (89.1) | 44 (10.1) | 0.93 |
| Present | 47 (66.2) | 24 (33.8) | | 63 (88.7) | 8 (11.3) | |
COPD | Absent | 315 (70.9) | 129 (29.1) | 0.07 | 398 (89.6) | 46 (10.4) | 0.08 |
| Present | 16 (55.2) | 13 (44.8) | | 23 (79.3) | 6 (20.7) | |
Asthma | Absent | 326 (71.0) | 133 (29.0) | < 0.01 | 410 (89.3) | 49 (10.7) | 0.20 |
| Present | 5 (35.7) | 9 (64.3) | | 11 (78.6) | 3 (21.3) | |
Arrhythmia | Absent | 321 (70.2) | 136 (29.8) | 0.50 | 407 (89.61 | 50 (10.9) | 0.84 |
| Present | 10 (62.5) | 6 (37.5) | | 14 (87.5) | 2 (12.5) | |
Autoimmune disease | Absent | 323 (69.9) | 139 (30.1) | 0.84 | 412 (89.2) | 50 (10.8) | 0.44 |
| Present | 8 (72.7) | 3 (27.3) | | 9 (81.8) | 2 (18.2) | |
Hypertension | Absent | 279 (69.7) | 121 (30.3) | 0.79 | 354 (88.5) | 46 (11.5) | 0.40 |
| Present | 52 (71.2) | 21 (28.8) | | 67 (91.8) | 6 (8.2) | |
Smoking status | Brinkman index < 600 | 180 (76.3) | 56 (23.7) | < 0.01 | 213 (90.3) | 23 (9.7) | 0.38 |
| Brinkman index ≥ 600 | 151 (63.7) | 86 (36.3) | | 208 (87.8) | 29 (12.2) | |
BMI | < 22.93 | 165 (70.8) | 68 (29.2) | 0.69 | 217 (93.2) | 16 (6.8) | < 0.01 |
| ≥ 22.93 | 166 (69.2) | 74 (30.8) | | 204 (85.0) | 36 (15.0) | |
CEA | ≤ 5 | 240 (72.7) | 90 (27.3) | 0.04 | 297 (90.0) | 33 (10.0) | 0.29 |
| > 5 | 91 (63.6) | 52 (36.4) | | 124 (86.7) | 19 (13.3) | |
PNI | ≥ 49.68 | 190 (73.9) | 67 (26.1) | 0.04 | 234 (91.1) | 23 (8.9) | 0.12 |
| < 49.68 | 141 (65.3) | 75 (34.7) | | 187 (86.6) | 29 (13.4) | |
NLR | ≤ 1.56 | 97 (78.2) | 27 (21.8) | 0.01 | 111 (89.5) | 13 (10.5) | 0.83 |
| > 1.56 | 234 (67.1) | 115 (32.9) | | 310 (88.8) | 39 (11.2) | |
%VC | ≥ 80 | 325 (70.4) | 137 (29.6) | 0.25 | 414 (89.6) | 48 (10.4) | < 0.01 |
| < 80 | 6 (54.6) | 5 (45.4) | | 7 (63.6) | 4 (36.4) | |
FEV1% | ≥ 70 | 231 (74.3) | 80 (25.7) | < 0.01 | 281 (90.4) | 30 (9.6) | 0.19 |
| < 70 | 100 (61.7) | 62 (38.3) | | 140 (86.4) | 22 (13.6) | |
Histological type | Non-Squamous cell carcinoma | 279 (71.2) | 113 (28.8) | 0.21 | 354 (90.3) | 38 (9.7) | 0.04 |
| Squamous cell carcinoma | 52 (64.2) | 29 (35.8) | | 67 (82.7) | 14 (17.3) | |
Operative approach | VATS or RATS | 295 (69.4) | 130 (30.6) | 0.42 | 380 (89.4) | 45 (10.6) | 0.40 |
| Open thoracotomy | 36 (75.0) | 12 (25.0) | | 41 (85.4) | 7 (14.6) | |
Operative procedure | RML or LLL | 90 (81.1) | 21 (18.9) | < 0.01 | 105 (94.6) | 6 (5.4) | 0.03 |
| RUL or RLL or LUL | 241 (66.6) | 121 (33.4) | | 316 (87.3) | 46 (12.7) | |
COPD; chronic obstructive pulmonary disease, CEA; carcinoembryonic antigen, PNI; prognostic nutritional index, NLR; neutrophil-to-lymphocyte ratio, VC; vital capacity, FEV1%; forced expiratory volume % in one second, VATS; video-assisted thoracic surgery, RATS; robotic-assisted thoracic surgery, RML; right middle lobectomy, LLL; left lower lobectomy, RUL; right upper lobectomy, RLL; right lower lobectomy, LUL; left upper lobectomy. |
Multivariate analyses of risk factors for postoperative morbidity and severe morbidity for patients who underwent lobectomy are shown in Table 7. The coexistence of asthma (OR 4.18, 95% CI 1.291–13.556, p=0.01) and the performance of RUL, RLL, or LUL (OR 2.21, 95% CI 1.277–3.823, p<0.01) were identified as significant risk factors for postoperative morbidity, while male sex (OR 2.35, 95% CI 1.152–4.818, p=0.01), a high BMI (OR 2.41, 95% CI 1.277-4.550, p<0.01), low %VC (OR 4.09, 95% CI 1.034–16.174, p=0.04), and performance of RUL, RLL, or LUL (OR 2.65, 95% CI 1.083–6.495, p=0.03) were identified as significant risk factors for severe postoperative morbidity.
Table 7
Multivariate analysis of risk factors for postoperative morbidity and severe morbidity in patients received lobectomy
Postoperative morbidity |
Variables | | Odds ratio | 95% CI | P value |
Comorbidity | Chronic renal failure | 4.82 | 0.809-28.755 | 0.08 |
| Asthma | 4.18 | 1.291-13.556 | 0.01 |
Smoking status | Brinkman index ≥ 600 | 1.45 | 0.930-2.266 | 0.10 |
CEA | > 5 | 1.37 | 0.878-2.156 | 0.16 |
PNI | < 49.68 | 1.40 | 0.921-2.130 | 0.11 |
NLR | > 1.56 | 1.49 | 0.903-2.477 | 0.11 |
FEV1% | < 70 | 1.30 | 0.828-2.051 | 0.25 |
Operative procedure | RUL or RLL or LUL | 2.21 | 1.277-3.823 | < 0.01 |
Postoperative severe morbidity |
Sex | Man | 2.35 | 1.152-4.818 | 0.01 |
BMI | ≥ 22.93 | 2.41 | 1.277-4.550 | < 0.01 |
%VC | < 80 | 4.09 | 1.034-16.174 | 0.04 |
Histology | Squamous cell carcinoma | 1.66 | 0.819-3.368 | 0.15 |
Operative procedure | RUL or RLL or LUL | 2.65 | 1.083-6.495 | 0.03 |
CEA; carcinoembryonic antigen, PNI; prognostic nutritional index, NLR; neutrophil-to-lymphocyte ratio, FEV1%; forced expiratory volume % in one second, RUL; right upper lobectomy, RLL; right lower lobectomy, LUL; left upper lobectomy, RUL; right upper lobectomy, RLL; right lower lobectomy, LUL; left upper lobectomy, BMI; body mass index, VC; vital capacity. |